PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

Prurigo nodularis (PN) is a chronic, debilitating cutaneous disease characterized by pruritic lesions and hyperkeratotic nodules presenting on the trunk and extremities. Given the intensity of pruritus as well as the lack of appropriate therapies to control the disease, PN is associated with a significantly reduced quality of life. The identified gaps in clinician knowledge indicate a need to educate dermatologists and other clinicians on the pathogenesis and diagnosis of PN. Clinicians also require education on emerging treatment options in an effort to improve confidence in integrating these therapies into clinical practice, once they become available, and reduce the overall burden of the disease.

FACULTY

Sonja Ständer, MD Professor of Dermatology and Neurodermatology Westfalian Wilhelms University of Münster Head, Interdisciplinary Center for Chronic Pruritus University Hospital Münster Münster, Germany

Gil Yosipovitch, MD Professor of Dermatology Stiefel Chair of Medical Dermatology Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery Miller School of Medicine University of Miami Director, Miami Itch Center Miami, Florida

Release date: July 29, 2022 Expiration date: July 29, 2023 Estimated time to complete activity: 45 minutes

TARGET AUDIENCE

This educational initiative has been designed for dermatology physicians, nurse practitioners, and physician assistants involved in the management of patients with PN.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Describe the burden of PN on sleep, psychosocial health, and other quality-of-life parameters
Identify known factors involved in the pathogenesis of PN to better understand and identify the condition when it is presented
Apply evidence-based guidance on the diagnostic workup for PN to aid in early diagnosis and prompt treatment
Cite the data for emerging therapies to improve confidence in integrating these agents into clinical practice after they become available

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 29, 2022 through July 29, 2023 participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity: Sonja Ständer, MD Consultant/Advisory Board: AbbVie, Almirall, Beiersdorf, Bellus Health, Benevolent, Bionorica, Cara, Celgene, CelloHealth, Clexio, DS Biopharma, Eli Lilly, Escient, Galderma, Grunenthal, Kiniksa, Klinge Pharma, Leo Pharma, Maruho, Menlo, Merz, P.G. Unna Academy, Perrigo, Pfizer, Sanofi, Sienna, Symbio Research, Trevi Therapeutics, Vanda, Vifor, WebMD Investigator: Celldex, Clexio, Dermasence, Galderma, GlaxoSmithKline, Kiniksa, Menlo, Novartis, Sanofi, Trevi Therapeutics, Vanda Research Grants: Almirall, Beiersdorf, German Research Foundation, European Academy of Dermatology and Venereology, German Federal Ministry of Education and Research, Interdisciplinary Center for Clinical Research Munster, Leo Pharma, Menlo, Novartis, Sanofi, Trevi Therapeutics Speaker: Sanofi Gil Yosipovitch, MD Consultant: Arcutis, Celldex, Eli Lilly, Galderma, Novartis, Pfizer, Regeneron, Sanofi, Trevi Therapeutics Research: Celldex, Eli Lilly, Galderma, Novartis, Pfizer, Regeneron, Sanofi, Trevi Therapeutics The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

The Dawning of a New Era in the Management of Prurigo Nodularis: A Focus on the Patient Experience, Differential Diagnoses, and Emerging Treatment Options